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ABSTRACT 
 
Objective:  Whether statins increase the risk of intracerebral hemorrhage (ICH) in patients 
with a previous stroke remains uncertain.  This study addresses the evidence of statin therapy 
on ICH and other clinical outcomes in patients with previous ischemic stroke (IS) or ICH. 
Methods: A systematic literature review and meta-analysis was performed in conformity with 
the PRISMA guidelines to assess observational and randomised studies comparing statin 
therapy with control (placebo or no treatment) in patients with a previous ICH or IS.  The risk 
ratios (RR) for the primary outcome (ICH) and secondary outcomes (IS, any-stroke, mortality 
and function) were pooled using random effects meta-analysis according to stroke subtype.   
Results:  Forty-three studies, with a combined total of 317,291 patient-years of follow-up were 
included.  In patients with previous ICH, statins had no significant impact on the pooled RR for 
recurrent ICH (1.04, 95% CI 0.86-1.25; n=23,695), however statins were associated with 
significant reductions in mortality (0.49, 0.36-0.67; n=89,976) and poor functional outcome 
(0.71, 0.67-0.75; n=9,113).  In patients with previous IS, statins were associated with a non-
significant increase in ICH (1.36, 0.96-1.91; n=103,525), but significantly lower risks of 
recurrent IS (0.74, 0.66-0.83; n=53,162), any-stroke (0.82, 0.67-0.99; n=55,260), mortality 
(0.68, 0.50-0.92; n=74,648) and poor functional outcome (RR 0.83, 0.76-0.91; n=34,700). 
Conclusions:  Irrespective of stroke subtype, there were non-significant trends towards future 
ICH with statins.  However, this risk was overshadowed by substantial and significant 
improvements in mortality and functional outcome amongst statin users.  
Registration: PROSPERO: CRD42017079863  
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Abbreviations 
AF   Atrial Fibrillation 
CEA   Carotid endartarectomy 
CI   Confidence interval 
HR   Hazard ratio 
ICH   Intracerebral hemorrhage 
OR   Odds ratio 
RCT   Randomised controlled trial 
RoBANS  Risk of Bias Assessment Tool for Nonrandomized Studies 
RR   Risk ratio 
TIA   Transient ischemic attack 
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INTRODUCTION 
Statin therapy has routinely been used to inhibit cholesterol synthesis and avoid cardiovascular 
events throughout the last three decades.  They are recommended by both American and 
European guidelines to reduce risk of stroke and cardiovascular events in patients with 
cerebrovascular disease.1 2  Despite the demonstrated beneficial effects of statins in preventing 
first ever stroke, prescriptions remain suboptimal with age, gender, racial and geographic 
discrepancies.3  This may partially be explained by concerns around the potential risk of 
intracerebral hemorrhage (ICH) with statins due to their anti-platelet and anti-coagulant effects, 
particularly in patients with a previous ICH.4 5 
 
In two large randomised trials, Stroke Prevention by Aggressive Reduction in Cholesterol 
Levels (SPARCL)6 and Heart Protection Study (HPS),7 the benefit in reducing recurrent 
ischemic stroke was offset in part by an increased risk of hemorrhagic stroke.  A risk benefit 
decision analysis of statin therapy in patients with prior ICH concluded that statin avoidance 
should be considered following ICH particularly in those with lobar ICH.8 Conversely, two 
meta-analyses of randomised trials enrolling patients without prior stroke found no significant 
association between statins and ICH with significant reductions in all-strokes and all-cause 
mortality with statin therapy.9 10 Additionally, statin use after ICH was associated with early 
neurological improvement at 6 months.11 There is, therefore, a clear imperative to define the 
place of statins in the clinical management of patients with a previous stroke at future risk of 
ICH. 
 
In view of the potential usefulness of statins in patients with a previous stroke, and in an 
attempt to settle the uncertainty over adverse clinical outcomes, we assessed the efficacy and 
safety of statins by comprehensively meta-analysing all available observational and 
experimental studies.  We aim to build on the previous meta-analyses by focusing on studies in 
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which patients had an established ischemic or hemorrhagic stroke.  We used meta-regression 
techniques to evaluate the association of study characteristics with the risk of clinical 
outcomes. 
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METHODS 
Eligibility criteria & search strategy 
All studies comparing clinical outcomes in participants treated with statins and control 
(placebo or no treatment) were evaluated, regardless of study design.  We excluded studies 
where statins were used for primary prevention or did not provide comparative outcomes.  
Studies assessing secondary prevention of cerebrovascular disease were included. The 
definitions of ICH and ischemic stroke used by each individual study were accepted.  A 
systematic review of MEDLINE (1960 to June 2017), EMBASE (1980 to June 2017) and the 
Cochrane Library (until June 2017 Issue) were performed.  The search strategy included 
keywords and MeSH terms relating to statins and ICH, ischemic stroke, death, and functional 
outcomes.  We manually searched reference lists of relevant studies, investigated registers of 
on-going trials and included studies after discussion with content experts.  The review was 
conducted according to the PRISMA guidelines and was prospectively registered with the 
PROSPERO database of systematic reviews (CRD42017079863).12  
 
Data collection, synthesis and risk of bias 
Two investigators (OJZ and GB) independently extracted and tabulated data in a standardised 
data extraction form.  Discrepancies and missing data were resolved by group discussion, 
reference to the original publication and additional independent adjudication (DJW).  All data 
were extracted from studies, including crude outcomes and adjusted analyses (multivariate 
adjustment and propensity-matched),  Careful note was made of the analysis method (including 
risk ratio [RR; preferred], odds ratio [OR] or hazard ratio [HR]) and the population studied.  
Risk of bias was assessed with the Cochrane Collaboration’s Risk of Bias tool for RCTs and 
the Risk of Bias Assessment Tool for Non-randomized Studies (RoBANS), which address key 
criteria including selection bias, exposure measurement, blinding and selectivity of reporting.  
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Assessment of bias risk was performed independently from data extraction, with each study 
assessed by two authors. 
 
Primary and Secondary Outcomes 
The predefined primary outcome was ICH.  Secondary outcomes included ischemic stroke, 
any-stroke, all-cause mortality and poor functional outcome.  The definitions used by each 
individual study were accepted.  To investigate whether treatment effects vary between stroke 
types, analyses were subgrouped by previous ICH and previous ischemic stroke. 
 
Statistical analysis 
Baseline demographics in the statin and control groups were compared using meta-analysis and 
summarised as the OR.  Random effects meta-analysis was pre-specified to combine estimates 
from different studies.  Pooled binary event data for statin and control cohorts were compared 
using a RR with associated 95% confidence intervals (CI) using the method of DerSimonian 
and Laird.  In cases where the OR was described, these were converted to RR (RR = OR / 
([1−pRef] + [pRef*OR]), where pRef is the prevalence of the outcome in the reference group).  
RR and corresponding CI were log-transformed before pooling.  HR were included in the 
systematic review but not meta-analysis due to a scarcity of results presented in this way.  
Where studies reported several results for the same outcome, we extracted the result based on 
the longest follow-up duration and most adjustment factors.  Sensitivity analyses were 
performed according to study design (randomised trials and observational cohorts).  The degree 
of heterogeneity between studies was quantitatively assessed using the I2 statistic (I2 of ≥50% 
indicates substantial heterogeneity, ≥75% suggests considerable heterogeneity).  Meta-
regression was performed to quantify the heterogeneity, assess the impact of baseline variables 
and risk of bias on estimates of each outcome, according to stroke subtype.  Publication bias 
was evaluated by inspection of funnel plots and quantitatively assessed using Begg’s and 
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Egger’s tests to identify small-study effects.  A p-value < 0.05 was considered statistically 
significant.  Analyses were performed using STATA version 13.1 (StataCorp LP, Texas).  
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RESULTS 
The search strategy identified 51 studies for systematic review, including 1,324,450 patients on 
statin therapy or control (placebo or no treatment) and 4,098,285 patient-years of follow-up 
(eFigure 1).  Of the 51 studies, 36 were observational,11 13-46 and 15 were randomised on the 
basis of statin therapy.6 7 47-59 Study descriptors are summarised in eTable 1.  Forty-three 
studies were suitable for inclusion in the quantitative meta-analysis comparing statins with 
control in patients with a previous stroke.  Of the 43 studies, 15 provided data on patients with 
a previous ICH6 11 17 34-36 38-44 47 48 and 29 reported outcomes in patients with a prior ischemic 
stroke.13-15 17-32 45 46 49-56  84,356 patients were taking statins (47.1%) compared to 94,597 in the 
control arms (52.8%).  The weighted average length of follow-up was 1.77 years with a range 
of 0.1-7.0.   
Differences in key characteristics between statin and control groups are summarised in Table 1 
(for full baseline demographics, see eTable 2).  Patients receiving statins had more diabetes, 
hypertension, hyperlipidemia and coronary artery disease than controls and were more often 
receiving anti-coagulant and anti-platelet drugs. 
Meta-analysis was performed for five outcomes: ICH, ischemic stroke, any-stroke, all-cause 
mortality and functional outcome.  A summary of the individual meta-analyses performed is 
presented in Figure 1 and detailed results are discussed below.  The risk of bias in individual 
studies is presented in eTables 3 and 4.  As expected, this was proportional to the robustness of 
study design, with RCTs having the lowest risk of bias.  There was no evidence of small study 
effects or publication bias in any of the outcomes assessed (all Eggers p>0.1). 
 
Population: Previous intracerebral hemorrhage 
Fifteen studies of patients with previous ICH were suitable for meta-analysis (n=50,374; Table 
2; Figure 2).6 11 17 34-36 38-44 47 48 
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Table 1:  Pooled weighted characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Meta-analysis of baseline demographics comparing statin-treated  
patients with control.  AF, atrial fibrillation, CAD, coronary artery  
disease, OR, odds ratio 
 
 
Table 2:  Summary of studies and patients according to cerebrovascular disease subtype 
Population Outcome 
Number of 
Studies 
Statin 
Patients 
Control 
Patients 
Total number 
of patients 
Patient-years 
of follow-up 
Systematic Review - 51 - - 1,324,450 4,098,285 
Meta-analysis - 43 84,356 94,597 178,953 317,291 
Previous intracerebral 
hemorrhage 
Total 15 7,645 42,729 50,374 91,467 
Recurrent ICH 3 3,052 20,643 23,695 62,930 
Ischemic stroke 1 45 48 93 456 
Any stroke 1 45 48 93 456 
All-cause mortality 15 57,189 32,787 89,976 87,954 
Poor functional 
outcome 
7 1,942 7,171 9,113 5,915 
Previous ischemic 
stroke 
Total 29 76,711 51,868 128,579 225,824 
ICH 11 64,005 39,520 103,525 210,509 
Recurrent ischemic 
stroke 
3 40,808 12,354 53,162 50,870 
Any stroke 7 41,643 13,617 55,260 59,078 
All-cause mortality 13 51,500 23,148 74,648 43,568 
Poor functional 
outcome 
19 15,858 18,842 34,700 31,907 
 
Baseline 
characteristic 
Statin vs. control arm 
(95% CI) 
p-value 
Male gender OR 1.08 (0.98-1.18) 0.11 
Diabetes OR 1.49 (1.31-1.69) <0.001 
AF OR 1.00 (0.88-1.14) 1.00 
Smoker OR 0.90 (0.73-1.12) 0.34 
Hypertension OR 1.54 (1.25-1.91) <0.001 
Hyperlipidemia OR 4.32 (2.29-8.13) <0.001 
CAD OR 2.05 (1.53-2.74) <0.001 
Anti-coagulant OR 1.71 (1.29-2.26) <0.001 
Anti-platelet OR 2.36 (1.69-3.30) <0.001 
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Outcome: Recurrent intracerebral hemorrhage 
One randomised and two observational studies of statins in patients with previous ICH 
reporting the outcome recurrent ICH were included (n=23,695).34 44 47  There was no difference 
in recurrent ICH between patients on statin and control (RR 1.04, 95% CI 0.86-1.25, P=0.70).  
Two additional studies providing HRs were both concordant with this neutral result.33 37 
Sensitivity analysis of study design demonstrated that although there was no significant 
difference between the randomised and observational studies, the observational studies had a 
noteworthy lower pooled relative risk than the randomised SPARCL subgroup (RR 1.02, 95% 
CI 0.89-1.16 vs. RR 3.73, 95% CI 0.83-17.0; see Figure 1A, eTable5). 
 
Outcome: Ischemic stroke 
One sub study of statins in patients with previous ICH (n=93) reported a non-significant 
increase in incident ischemic stroke (RR 1.60, 95% CI 0.28-9.14).47 
 
Outcome: Any stroke 
One sub study of statins in patients with previous ICH (n=93) reported a non-significant 
increase in any-stroke (RR 2.67, 95% CI 0.90-7.90, P=0.08).47   
 
Outcome: All-cause mortality 
In 15 studies with previous ICH (n=89,976) there was a significant reduction in all-cause 
mortality with statins versus control (RR 0.49, 95% CI 0.36-0.67, P<0.001) but with significant 
heterogeneity (I2 = 91.7%, P<0.001).6 11 17 34-36 38-41 43 48  Two additional studies reporting HRs 
were consistent with this finding.33 42 Sensitivity analysis of study design demonstrated that 
observational studies had a lower pooled relative risk than the randomised analyses (RR 0.46, 
95% CI 0.33-0.63 vs. RR 1.03, 95% CI 0.47-2.49; see eTable5). 
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We performed an exploratory meta-regression of the impact of differences in key baseline 
characteristics on all cause mortality between statin and control patients.  This analysis 
demonstrated that the mortality of benefit of statins was diminished when the statin group was 
composed of a smaller proportion of males than the control cohort (P=0.003; eTable 5).  
Additionally a greater mortality benefit with statins was associated with a more recent year of 
publication (P=0.01). 
 
Outcome: Poor functional outcome 
Seven studies of patients with previous ICH reported functional outcome (n=9,113), 
demonstrating a significant reduction in poor functional outcome amongst statin-users 
compared to control (RR 0.71, 95% 0.67-0.75, P<0.001).11 17 36 40-43  
 
Population: Previous ischemic stroke 
Twenty-nine studies of patients with previous ischemic stroke were suitable for meta-analysis 
(n=128,579; Table 2; Figure 3).13-15 17-32 45 46 49-56  
 
Outcome: Intracerebral hemorrhage 
Eleven studies of statins in patients with prior ischemic stroke reporting ICH were included 
(n=103,525).15 18-21 23 26 29 45 51 52 There was a non-significant increase in ICH with statins 
compared to control (RR 1.36, 95% CI 0.96-1.91; P=0.08) but with substantial heterogeneity 
(I2 = 79.3; P<0.001).  In studies that enrolled only patients with an ischemic stroke undergoing 
thrombolysis for ischemic stroke there was a non-significant increase in ICH with statins (RR 
1.61, 95% CI 0.77-3.34; P=0.20) compared with the remaining 6 studies without thrombolysis 
(RR 1.21, 95% CI 0.83-1.76; P=0.33).15 18 19 29 45 Sensitivity analysis of study design 
demonstrated that observational studies had a lower pooled relative risk than the randomised 
trials (RR 1.73, 95% CI 1.20-2.49 vs. RR 1.28, 95% CI 0.85-1.93; see eTable5). 
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An exploratory meta-regression of the effect of study-level bias demonstrated that studies with 
lower bias reported a greater association of statins with ICH (P=0.017; eFigure 2).  This was 
supported by a sensitivity analysis of study design, where the pooled 2 randomised trials 
reported a significant increase in ICH (RR 1.73, 95% CI 1.20-2.49; P=0.004), whilst the 9 
observational studies reported a neutral association (RR 1.28, 95% CI 0.85-1.93; P=0.23).  
Meta-regression was used to explore the impact of differences in key baseline characteristics 
between statin and control patients on ICH.  This revealed that studies with a similar incidence 
of hyperlipidemia in both the statin and control groups were associated with increased ICH 
with statins (P=0.002).  Conversely, studies where patients had a higher incidence of 
hyperlipidemia in the statin group compared to control were associated with reduced ICH with 
statins.  Additionally studies with larger proportion of males in the statin arm were more likely 
to report an increase in ICH with statins (P=0.025) 
 
Outcome: Recurrent ischemic stroke 
Three studies of patients with previous ischemic stroke (n=53,162) revealed a reduction in 
recurrent ischemic stroke with statins compared to control (RR 0.74, 95% CI 0.66-0.83; 
P<0.001).23 51 52  Two additional studies reporting HRs were both consistent with this 
outcome.21 60  
 
Outcome: Any stroke 
Seven studies with previous ischemic stroke were included (n = 55,260).23 46 49-52 54  There was 
a borderline significant reduction in any-stroke with statins compared to control (RR 0.82, 95% 
CI 0.67-0.99; P=0.04) but with significant heterogeneity (I2 = 72.9; P=0.001).   
 
Outcome: All-cause mortality 
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In 13 studies pertaining to the prior ischemic stroke cohort (n=74,648), there was a reduction in 
all-cause mortality with statins compared to control (RR 0.68, 95% CI 0.50-0.92, P=0.01) 13 17 
18 23 25 29 30 32 45 46 52 55 56 but with considerable heterogeneity (I2 = 86.5; P<0.001).  Two 
additional analyses reporting HRs both demonstrated significant reductions in mortality.16 22 
Sensitivity analysis of study design demonstrated that although there was a significant 
reduction in mortality in the pooled observational studies (RR 0.60, 95% CI 0.42 – 0.85) there 
was no statistical difference in the pooled randomised analyses (RR 1.04, 95% CI 0.87 – 1.24; 
eTable 5). 
 
 
Outcome: Poor functional outcome 
Twenty-one analyses (n=34,700) in 19 studies of patients with prior ischemic stroke reported 
functional outcome.  Together these demonstrated that statin use was significantly associated 
with a reduction in poor functional outcome compared to control (RR 0.83, 95% CI 0.76-0.91, 
P<0.001) albeit with significant heterogeneity (I2 = 85.8; P<0.001).13 14 17-19 22 24-32 45 52 53 56 
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DISCUSSION 
In our comprehensive meta-analysis including a combined total of over 300,000 patient-years of follow-up 
we found that in patients with a previous ICH, statins were not associated with an increased risk of 
recurrent ICH.  In patients with previous ischemic stroke, we found a clear benefit of statins in reducing 
recurrent ischemic stroke at the expense of a non-significant increase in ICH.  Statins were associated with 
substantial and significant improvements in mortality and functional outcome irrespective of stroke 
subtype.  
 
Previous intracerebral hemorrhage 
Statins exert beneficial cardiovascular pleotropic effects on endothelial dysfunction through normalising 
vasomotion, increasing bioavailability of nitric oxide and supressing inflammatory responses.61  However, 
the anti-platelet and anti-coagulant effects of statins have raised concerns that they may increase the risk of 
ICH.  Statins have also been hypothesised to have potentially harmful consequences in acute ICH where 
their diverse pharmacological properties may contribute to hematoma expansion.62  In both the HPS and 
SPARCL trials, which enrolled patients with a previous stroke, statins were associated with increased ICH 
compared to placebo.7 52  Of these two trials, only SPARCL provided a subgroup analysis of patients with a 
previous hemorrhagic stroke, demonstrating a non-significantly increased risk of recurrent ICH.47 In 
contrast, four larger observational cohort studies all demonstrated a neutral effect of statins on recurrent 
ICH.33 34 37 44, consistent with our findings.  
We found that in ICH survivors statins were associated with improved mortality and functional outcome 
with no significant effect on recurrent ICH.  We were unable to meta-analyse the outcomes ischemic stroke 
and any stroke-type as the only data available was from the hemorrhagic stroke subgroup population of the 
SPARCL trial (n=93).47 These results do not support withholding statins after ICH, but large randomised 
controlled trials are still needed to consolidate these findings.  
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Most intracerebral hemorrhages are due to cerebral small vessel disease hypertensive arteriopathy 
(arteriolosclerosis), which affects deep perforating vessels, and cerebral amyloid angiopathy (CAA), which 
affects superficial cortical and leptomeningeal vessels.  Thus, whilst hypertension is the strongest risk 
factor for deep ICH, a substantial proportion of lobar ICH are due to CAA.  CAA has a high recurrence 
risk (7·4% per year in a pooled analysis of cohort studies63) so has caused the strongest concerns regarding 
statin use.  Observational and randomised data suggest that recurrent ICH can be reduced by anti-
hypertensive therapy,64 however CAA currently lacks any specific preventative therapy.  A retrospective 
analysis found that statins in patients with ICH was associated with microbleeds on MRI, particularly of 
cortico-subcortical distribution, commonly observed in CAA.65  Thus, although our findings are reassuring, 
we were unable to stratify by ICH location or presumed cause, so decisions in ICH survivors require an 
individualised patient assessment of indication, comorbidity and the goal of statin therapy.  Unsurprisingly, 
amongst stroke physicians the use of statins in patients following ICH remains contentious.  American 
guidelines recommend statins in patients with ICH due to insufficient data to advise restriction (Class IIb; 
Level C) whilst European guidelines do not address the issue.1 2  Unfortunately, the only double blinded 
placebo controlled RCT of statins in patients with ICH (NCT00718328) terminated early due to poor 
recruitment.  
 
Previous ischemic stroke 
In survivors of ischemic stroke, statins were associated with substantial and significant improvements in 
mortality, functional outcome and ischemic stroke, with a non-significant trend towards increased ICH.  
Although epidemiological data indicate a modest link between high serum LDL and greater risk of 
ischemic stroke, they have also pointed towards an association of low LDL and a heightened risk of ICH.66  
By reducing serum cholesterol, statins may reduce the integrity of the vasculature leading to arterial 
necrosis and microaneurysm formation.67  A previous meta-analysis of randomised trials of statins for 
primary and secondary prevention of stroke demonstrated significant reductions in LDL and ischemic 
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stroke risk in both primary and secondary prevention, but a significant increase in ICH was identified in 
secondary prevention trials.68 This finding was largely based on the only dedicated secondary prevention 
trial of stroke, SPARCL, which identified a significant reduction in recurrent ischemic stroke but with a 
higher incidence of ICH.59  Similarly in the HPS trial previous stroke subgroup, there was a 91% increased 
risk in hemorrhagic stroke with statins.7   We found that when these trials are combined with observational 
studies and limited to secondary prevention, this ICH risk persists, albeit non-significantly.   
Nevertheless, given the potentially increased risk of ICH with statin treatment, physicians should have 
caution in recommending statins to individuals with risk factors for ICH.  Indeed, we found substantial 
heterogeneity in treatment effect indicating a “one size fits all” approach to statins may be inappropriate.  
For example, whilst the effectiveness of statin therapy in patients with previous ischemic stroke due to 
atherosclerotic disease is clear, in those due to atrial fibrillation (AF) the evidence is less obvious.  Indeed 
stroke patients with AF, who were excluded from SPARCL, often have higher bleeding risks due to 
concomitant anticoagulation.52 Another important concomitant therapy to consider is thrombolysis, which 
further adds to the hemorrhagic transformation risk.4 5  The results of our sensitivity analysis confirmed 
that statins increased the risk of ICH in patients with ischemic stroke treated with thrombolysis.  Age is 
another important component of bleeding risk.  Unfortunately numerous statin trials excluded frail elders 
casting doubt on how results might translate to those over 80 years old.  Only with careful patient selection 
can an optimal balance between efficacy and safety be achieved. 
If statins are considered in stroke survivors, then further contentious questions arise including: (i) which 
statin; (ii) what dose; (iii) when to initiate; (iv) and when to withdraw.  With regard to agent and dose, the 
on-going Treat Stroke to Target (TST) trial (NCT01252875) will provide clarity on targeted LDL levels 
and vascular events amongst survivors of ischemic stroke.  Regarding timing, surrogate marker studies 
indicate a role of statins in the acute phase of ischemic stroke through upregulation of nitric oxide, 
fibrinolytic and antithrombotic mechanisms, however the major statin trials typically did not enrol patients 
until ~3 months post stroke.52 69  The only randomised trial to investigate timing per se demonstrated no 
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improvement in neurologic function at 90 days with early (<24 hours) versus delayed (7 days) therapy, 
although included patients had low stroke severity who may not have substantial disease substrate to 
benefit.70 
As statins are often not prescribed until clinicians detect presence of cardiovascular disease risk factors, 
treatment with statins is likely to be influenced by the probability of ICH, creating “confounding by 
indication.” We have demonstrated differences in baseline characteristics between patients in statin and 
control groups in observational studies and exposed their impact on ICH through meta-regression analysis.  
These differences may partly explain the conflicting results between randomised and observational 
studies,21 45 a problem not exclusive to stroke trials.71  
Taking all studies into account, despite prescription biases the net effect of statin use appears clearly 
beneficial for mortality and functional outcome, even though an increased risk of ICH may partly offsets 
these improvements.  Our findings thus suggest that statins should continue to be considered in those with 
a previous stroke (including ICH) to reduce mortality and improve functional outcome, but caution should 
be taken in individuals at high risk for ICH (e.g. older anticoagulated patients with poorly controlled 
hypertension or CAA).  In these patients alternative approaches to manage hyperlipidemia should be 
considered, for instance through upregulation of LDL receptors using the novel PCSK9 inhibitors.72   
 
Limitations 
Our review is based on published data of independent studies, performed in accordance with explicit, 
reproducible methodology.  While meta-analysis of individual patient data is ideal, it is unrealistic with 
such large data groupings across a wide number of studies.  We recognise a number of drawbacks of our 
study.  Firstly there is a deficiency in sample sizes from both randomized and observational studies to 
generate adequately powered pooled effect estimates especially in the previous ICH cohort.  There was 
insufficient data to perform meta-analysis of statin dose, statin type or the impact of location of ICH (lobar 
versus deep).  Second, definitions of ICH and ischemic stroke between studies differed with potential for 
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miscategorisation.  Although some studies precisely reported the stroke aetiology, type and severity, many 
did not.  Third, due to expected disparities in study designs and populations, we pre-specified a random-
effects model.  Indeed, we noted substantial heterogeneity in treatment effect for many of the assessed 
outcomes.  However, most of the heterogeneity was caused by the effect magnitude instead of the effect 
direction.  Finally, although no signal of publication bias was identified, statistical assessments can be 
misrepresentative particularly with considerable heterogeneity.73   
 
Conclusion 
In patients with ICH, statins did not increase recurrent ICH.  In survivors of ischemic stroke, although 
statins substantially and significantly reduced recurrent ischemic stroke, there was a non-significant 
increase in ICH.  Nonetheless, statins show clear benefits in reducing mortality and improving functional 
outcome irrespective of stroke subtype.  These results were predominantly based on observational data 
with insufficient randomised trial data available.  Given that observational data is subject to inherent 
confounding, future randomised trials of statins in patients with cerebrovascular disease (especially ICH 
survivors) are required to clarify the safety of this therapy on future ICH risk. 
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Figure Legends 
 
Figure 1: Summary of meta-analyses in observational and randomised studies on 
safety and efficacy of statins in patients with previous stroke 
(Total studies). See Figures 2 and 3 for study-level results. 
 
Figure 2: Forest Plot of Studies on Association Between Statins and Clinical Outcomes 
in patients with previous intracerebral hemorrhage  
The diamond represents the pooled difference using a random-effects model.  I2 is the 
percentage of total variation across studies due to heterogeneity. Eggers test of small-study 
effects: ICH p = 0.16; all-cause mortality p = 0.88; poor functional outcome p = 0.58.  Poor 
functional outcome was defined as mRS >2 by all studies except Dowlatshahi which defined 
as mRS >3, Tapia-Perez 2013 and 2016 which defined as NIHSS >15, and Winkler which 
defined as mBI <15. CT, computed tomography; ICD, international classification of 
diseases; ICH, intracerebral hemorrhage. 
 
Figure 3. Forest Plot of Studies on Association Between Statins and Clinical Outcomes 
in patients with previous ischemic stroke  
The diamond represents the pooled difference using a random-effects model.  I2 is the 
percentage of total variation across studies due to heterogeneity.  CEA, carotid 
endartarectomy; TIA, transient ischemic attack; tPA, tissue plasminogen activator.  Eggers 
test of small-study effects: ICH p = 0.78; ischemic stroke p = 0.30; any-stroke p = 0.52; all-
cause mortality p = 0.54; poor functional outcome p = 0.69.  Poor functional outcome was 
defined as mRS >2 by all studies except Alvarez-Sabin and Song, which defined as being 
dependent and Leker as mRS >3.  
 
